Donald Steely, MD
Interventional Cardiology · Conway, ARNPI 1700855921
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,279 of the $9,553 with a category attached, or 65.7%. 29 manufacturers reported payments, led by Medtronic at 45.7% of the total. Reporting peaked in 2019 at $5,288 and has fallen 86.6% since, to $709 in 2025.
Across 357 payments — averaging $26.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Novartis$1K
- Merck$441
- Pfizer$431
- Johnson & Johnson$393
- Amgen$368
- plus $2K from 23 others
What the payments were for
- Travel & lodging$3,02232%
- Food & beverage$6,27966%
- Education$2533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 44 | $4,361 |
| Novartis | 82 | $1,282 |
| Merck | 28 | $441 |
| Pfizer | 32 | $431 |
| Johnson & Johnson | 29 | $393 |
| Amgen | 21 | $368 |
| Actelion Pharmaceuticals US, Inc. | 14 | $300 |
| Sanofi-aventis U.S. LLC | 16 | $263 |
| AstraZeneca | 17 | $249 |
| E.r. Squibb & Sons, L.L.C. | 12 | $202 |
| Astellas Pharma US Inc | 3 | $188 |
| Boehringer Ingelheim | 11 | $167 |
| Irhythm Technologies, Inc. | 9 | $132 |
| Boston Scientific | 6 | $116 |
| Baxter Healthcare | 4 | $93 |
| Abbott | 4 | $88 |
| Novo Nordisk | 5 | $82 |
| Lexicon Pharmaceuticals, Inc. | 3 | $70 |
| Abiomed | 1 | $65 |
| Bayer | 3 | $44 |
| Cathworks, Inc. | 1 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $31 |
| Shockwave Medical, Inc | 1 | $25 |
| Cook Medical LLC | 1 | $23 |
| Philips North America LLC | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Cashflow Solutions, LLC | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,173
- Advisa$874
- Azure$131
- Arctic Front$107
How this compares
$9,553 in reported general payments places this provider in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 697 | $566,035 |
| EntrestoSacubitril/Valsartan | 530 | $419,208 |
| XareltoRivaroxaban | 243 | $201,447 |
| JardianceEmpagliflozin | 77 | $55,041 |
| MultaqDronedarone Hcl | 52 | $45,451 |
| Repatha SureclickEvolocumab | 53 | $33,359 |
| FarxigaDapagliflozin Propanediol | 34 | $29,043 |
| BrilintaTicagrelor | 44 | $22,345 |
| Praluent PenAlirocumab | 24 | $15,719 |
| Ranolazine ErRanolazine | 243 | $14,844 |
| Metoprolol Succinate | 688 | $7,841 |
| VerquvoVericiguat | 13 | $7,463 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,009 |
| Dofetilide | 43 | $4,979 |
| Rosuvastatin Calcium | 395 | $4,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $431 | $566,035697 claims |
| NovartisEntresto | $1,282 | $419,208530 claims |
| Johnson & JohnsonXarelto | $393 | $201,447243 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $167 | $61,05088 claims |
| AstraZenecaFarxiga, Brilinta | $249 | $51,38878 claims |
| Sanofi-aventis U.S. LLCMultaq | $263 | $45,45152 claims |
| MerckVerquvo | $441 | $7,46313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Conway
- Lensey ScottConway$14K
- Lloyd NorrisConway$9K
- Rimsha HasanConway$5K
- Omar YacobConway$5K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.